Biotech entity
funding is the sole category represented across all 1 tracked stories. 3D Bio Intelligence is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Xellar Biosystems appears in 1 tracked Biotech story from July 25, 2026.
Last mentioned: Jul 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
funding is the sole category represented across all 1 tracked stories. 3D Bio Intelligence is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Xellar Biosystems appears in 1 tracked Biotech story from July 25, 2026. The tracked stories average 1 original source each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Xellar Biosystems. Shared-story counts are live from our verified record — not editorial picks.
Xellar Biosystems' $50M Series A financing accelerates the development of a closed-loop 3D Bio Intelligence platform, combining organ-on-chip and AI to generate human-relevant data. The biotech aims to solve the preclinical data bottleneck that plagues drug discovery, with implications for reducing clinical trial failures.
Source: prnewswire.com
Xellar Biosystems is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
